Ouabain at nanomolar concentrations is cytotoxic for biliary tract cancer cells

Christian Mayr1,2, Tobias Kiesslich1,2, Dino Bekric1

  • 1Center of Physiology, Pathophysiology and Biophysics, Institute of Physiology and Pathophysiology Salzburg, Paracelsus Medical University, Salzburg, Austria.

Plos One
|June 30, 2023
PubMed

Insights

Ouabain shows potential as an anti-cancer drug for biliary tract cancer. Low concentrations of ouabain reduce cancer cell viability and induce apoptosis, independent of Na+/K+-ATPase inhibition.

Area of Science:

  • Oncology
  • Pharmacology
  • Cell Biology

Background:

  • Biliary tract cancer (BTC) has limited treatment options.
  • Ouabain inhibits Na+/K+-ATPase but may have anti-cancer effects independent of this function.
  • No prior data exists on ouabain's effect on BTC.

Purpose of the Study:

  • To investigate ouabain as a potential anti-neoplastic agent for BTC.
  • To evaluate ouabain's efficacy in human BTC in vitro models.
  • To explore the mechanism of ouabain's cytotoxic effects in BTC.

Main Methods:

  • Utilized comprehensive human BTC in vitro models (2D and 3D cell cultures).
  • Assessed ouabain's cytotoxic effect and determined IC50 values.
  • Investigated the association with Na+/K+-ATPase subunit expression.
  • Analyzed the mode of cytotoxicity, including apoptosis induction and membrane potential.
  • Evaluated ouabain's impact on spheroid growth in 3D models.

Main Results:

  • Ouabain exhibited a strong, cell line-dependent cytotoxic effect on BTC cells (nanomolar IC50).
  • Cytotoxicity was not correlated with Na+/K+-ATPase subunit mRNA expression.
  • Ouabain induced apoptosis in BTC cells.
  • Low-concentration ouabain's effects were independent of membrane depolarization and intracellular sodium changes.
  • Ouabain disrupted spheroid growth and reduced cell viability in 3D models.

Conclusions:

  • Ouabain demonstrates anti-BTC potential at low micromolar concentrations in vitro.
  • Ouabain's anti-cancer mechanism in BTC appears independent of Na+/K+-ATPase inhibition.
  • Further research into ouabain for BTC treatment is warranted.